Although it was suggested that TRPV1 antagonism might be associated with a risk of skin tumor development via EGFR/Akt signaling, more recent study have shown that two commercially available TRPV1 antagonists (AMG-9810 and SB-705498) do not affect human keratinocytes proliferation in vitro as well as do not have an impact on the skin carcinogenesis in mouse study (59, 60). Here, TRPV1 is linked to skin neoplasm.